11 results about "Secretin" patented technology

The invention discloses an anti-aging composition and a preparation method thereof, and belongs to the technical field of cosmetics, the anti-aging composition provided by the invention is prepared from the following components in parts by mass: 0.001-0.01 part of freeze-dried powder of secretin of porcine umbilical cord mesenchymal stem cells, 15-20 parts of argania spinosa leaf extract, 10-13 parts of eucheuma gelatinae extract and 1-3 parts of northeast stichopus japonicus adventitious root extract. The anti-aging composition provided by the invention has the effects of resisting aging and improving the migration rate of skin cells, and the whole anti-aging composition is mild and non-irritant; when the anti-aging composition is applied to cosmetics, the anti-aging composition can effectively resist aging, lighten wrinkles, improve skin elasticity and increase the water content of cuticles. In addition, the composition provided by the invention is natural in component source, simple in preparation method and suitable for actual production.

The present invention relates to an obesity-preventing or pharmaceutical composition and health functional food, comprising a garcinia cambogia extract. Specifically, the obesity-preventing or pharmaceutical composition comprises: an exothermic agent; a complex formulation; a branched chain amino acid (BCAA) containing one or more selected from the group consisting of leucine, isoleucine, and valine; calcium pantothenate; nicotinamide; crystalline cellulose; magnesium stearate; hydroxypropyl methylcellulose; and calcium carboxymethylcellulose, the complex formulation including a garcinia cambogia extract, an ephedra extract, and an active amino acid, wherein the temperature of the obesity-preventing or pharmaceutical composition is 5 to 10°C, and the exothermic agent releases heat when reacting with secretin and thus raises the temperature of the obesity-preventing or pharmaceutical composition to 20-25°C, inclusive.

The invention discloses bifidobacterium lactis BL-99 bacteriocin as well as a preparation method and antioxidant application thereof, the bifidobacterium lactis BL-99 bacteriocin comprises exocytosis of the bifidobacterium lactis BL-99 and metabolite of the bifidobacterium lactis BL-99, the mass ratio of citric acid to L-methionine in the bacteriocin is greater than 2: 1, and the preservation number of the bifidobacterium lactis BL-99 is CGMCC (China General Microbiological Culture Collection Center) No.15650. The bifidobacterium lactis BL-99 bacteriocin disclosed by the invention has an antioxidant function, can be applied to foods and medicines, and compared with a mixture comprising complete dead cells, cell wall components, cell membrane components and acellular supernatant, the bacteriocin disclosed by the invention is liquid or water-soluble powder, and has more advantages when being used in some liquid beverages and medicines.

The invention discloses bifidobacterium longum subsp. Infantis YLGB-1496 bacteriocin as well as a preparation method and antioxidant application thereof, the bifidobacterium longum subsp. Infantis YLGB-1496 bacteriocin comprises exocytosis of the bifidobacterium longum subsp. Infantis YLGB-1496 and metabolite of the bifidobacterium longum subsp. Infantis YLGB-1496, the mass ratio of citric acid to L-methionine in the bacteriocin is greater than 25: 1, and the mass ratio of citric acid to L-methionine is greater than 1: 1. The preservation number of the bifidobacterium longum subsp. Infantis YLGB-1496 is CCTCC (China Center For Type Culture Collection) No.M2011122. The bifidobacterium longum subsp The bifidobacterium longum subsp. Infantis YLGB-1496 bacteriocin disclosed by the invention has an antioxidant function, can be applied to foods and medicines, and compared with a mixture comprising complete dead cells, cell wall components, cell membrane components and cell-free supernatant, the bacteriocin disclosed by the invention is liquid or water-soluble powder, and has more advantages when being used in some liquid beverages and medicines.

The present invention relates to selective GLP1R agonists. In particular, the present invention relates to the discovery that secretin (SCT) can be converted into a high-potency and high-selectivity GLP1R agonist.

A pituitary adenylate cyclase activating peptide (PACAP) is a neuropeptide associated with a broad range of functions such as nociceptive feelings and primary headache. PACAP is a member of the trypsin / vasoactive intestinal peptide (VIP) / growth hormone releasing hormone (GHRH) family. The present disclosure relates generally to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

The invention relates to the use of a probiotic composition comprising a lactic acid producing bacterial strain, a conditioned medium or microvesicles from the lactic acid producing bacterial strain in treatment or prevention of hyposecretinemia. The lactic acid producing bacterial strain, the conditioned medium and / or the microvesicles is or are capable of inducing release, and optionally production, of secretin locally in a gastrointestinal tract of a subject suffering from hyposecretinemia or having a risk of suffering from hyposecretinemia. The invention also relates to screening of lactic acid producing bacterial strains suitable in treatment or prevention of hyposecretinemia. Secretin

Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide involved in a wide range of functions, including nociception and primary headaches. PACAP is a member of the secretin / vasoactive intestinal peptide (VIP) / growth hormone-releasing hormone (GHRH) family. The present disclosure generally relates to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods for producing and using such antibodies. For example, the present invention provides an anti-pituitary adenylate cyclase-activating polypeptide (PACAP) antibody, comprising the full-length heavy chain amino acid sequence set forth in SEQ ID NO:1 and the full-length light chain amino acid sequence set forth in SEQ ID NO:2.

The present invention relates to selective GLP1R agonists. In particular, the present invention relates to the finding that the secretin (SCT) may be converted into highly potent and selective GLP1R agonists.

This invention relates to the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction, belonging to the field of biomedical technology. This invention provides the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction. Cell model, gene knockout, in vivo complementation, and exogenous protein intervention experiments were conducted, revealing that secretin has significant in vitro and in vivo protective effects against steatohepatitis associated with metabolic dysfunction. In vitro, secretin can significantly improve oleic acid-induced lipid accumulation in hepatocytes, inhibit abnormal accumulation of lipid droplets in hepatocytes, reduce the expression of inflammatory factors in hepatocytes, alleviate hepatocyte inflammatory damage caused by lipotoxicity, and enter hepatocytes through endocytosis. It can alleviate high-fat diet-induced hepatic steatosis and inflammatory infiltration in MASH mice, and reduce the degree of liver fibrosis.